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Tyrosine phosphorylations are essential in signal transduction. Recently, a new type of phosphoty-
rosine binding protein, MEMO (Mediator of ErbB2-driven cell motility), has been reported to bind
speciﬁcally to an ErbB2-derived phosphorylated peptide encompassing Tyr-1227 (PYD). Structural
and functional analyses of variants of this peptide revealed the minimum sequence required for
MEMO recognition. Using a docking approach we have generated a structural model for MEMO/
PYD complex and compare this new phosphotyrosine motif to SH2 and PTB phosphotyrosine
motives.
Structured summary of protein interactions:
ErbB2 physically interacts with MEMO by pull down (View interaction 1, 2, 3, 4, 5, 6)
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction followed by transphosphorylation of speciﬁc tyrosine residues inReceptor tyrosine kinases are major players in transduction of
extracellular cues into intracellular signals that allow a cell to
adjust to the environment. Members of the ErbB family are trans-
membrane receptor kinases expressed in many different tissues.
These epidermal growth factor receptors play a crucial role in cell
growth, differentiation and migration. Aberrant expression of
receptor tyrosine kinases leads to dramatic physiological conse-
quences such as malignant tumor formation. For instance, overex-
pression of the ErbB2/Her2/Neu receptor tyrosine kinase in breast
cancers is associated with the most aggressive tumors [1,2]. Exper-
imental studies have revealed the contribution of ErbB2 to tumor
formation and ErbB2 is now considered as a therapeutic target in
breast cancer [3]. Ligand binding to the extracellular regions of
the ErbB receptors induces the formation of speciﬁc homo- or
heterodimeric receptor complexes, leading to kinase activationchemical Societies. Published by E
1, Marseille, France (A. Bad-
erlesquin).
he), guerlesq@ibsm.cnrs-mrs.the cytoplasmic tail.
Src homology 2 (SH2) and phosphotyrosine binding (PTB)
domains are the major domains recognizing phosphotyrosine
(pTyr) residues in receptor tyrosine kinases [4,5]. The overall struc-
ture of PTB domains and the mechanisms by which they bind both
pTyr residues and associated proximal amino acid residues differ
dramatically from SH2 domains. While SH2 domain binding is
strongly dependent on the presence of both the pTyr residue and
adjacent amino-acids carboxy-terminal to the pTyr residue, recog-
nition residues for PTB domains are located amino-terminal to the
pTyr [6,7]. Systematic search for proteins associating with phos-
phorylated tyrosine residues of ErbB cytoplasmic domains indi-
cated that most ErbB2-binding proteins harbor one of the two
types of domains [8]. However, recently, MEMO (Mediator of
ErbB2-driven cell motility) was described as a new class of phos-
photyrosine binding protein that binds to a phosphorylated
tyrosine (Tyr1227 in rat, Tyr1222 in human, also referenced as
TyrD) encompassing peptide of ErbB2 [9]. MEMO is an effector of
ErbB2 involved in breast carcinoma cell migration [10]. MEMO
contributes to localize the small G protein RhoA and its effector
mDia1 at the plasma membrane and controls microtubules
dynamics, formation of adhesion sites and recruitment oflsevier B.V. All rights reserved.
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binant protein demonstrated that MEMO can directly bind to
pTyrD-containing peptide (PYD1–16), in the absence of additional
factors [9]. Analysis of the primary sequence or the 3D structure of
MEMO does not reveal the presence of PTB or SH2 domains. How-
ever, MEMO is structurally related to bacterial dioxygenases [9].
Although, it was postulated that MEMO binds to the phosphory-
lated TyrD through its vestigial active site, its mode of interaction
with the phosphorylated peptide could not be described by X-ray.





Fig. 1. (A and C) Sequences of PYD1–16, and PYD4–13, truncated and mutant peptides us
experiments showing the binding of MEMO to the TyrD containing peptides shown in (A
pulled down using streptavidin-sepharose and analyzed by Western blotting using anti-
was quantiﬁed by densitometric analysis of the Western blots. Results were expressed r
are represented. ⁄P < 0.05, one way ANOVA-Bonferroni analysis.2. Materials and methods
2.1. Peptide synthesis
Seven peptides derived from PYD1–16 were produced by
EZBiolab: PYD1–16 (SPAFDNLYpYWDQDPPE) and YD1–16 (SPA-
FDNLYYWDQDPPE) peptides correspond to amino-acids 1214–
1229 from human ErbB2 phosphorylated or not on Tyr1222;
PYD1–10 (SPAFDNLYpYW), PYD4–13 (FDNLYpYWDQD) and
PYD7–16 (YpYWDQDPPE) are truncated peptides; PYDD/A
(SPAFANLYpYWAQAPPE) is a triple mutant of PYD1–16 (D5A,ed in (B and D). (B) Peptide binding activity of MEMO to PYD1–16 variants. Pulldown
). Biotinylated peptides, incubated with MEMO-expressing SKBr3 cell lysates, were
MEMO antibodies. (D) The amount of MEMO bound to the peptides indicated in (C)
elative to control PYD4–13 peptide. Mean and S.E.M. of three independent analyses
2690 M. Feracci et al. / FEBS Letters 585 (2011) 2688–2692D11A and D13A); ﬁnally, PYDpY/E (SPAFDNLYEWDQDPPE) is a
mutant of PYD1–16 in which the pTyrD (pTyr9) residue was re-
placed by a glutamate residue. Three peptides derived from
PYD4–13 were synthesized by Schafer-N: PYDF4A (ADNLY-
pYWDQD) has the F4A mutation, PYDY8A (FDNLApYWDQD) has
the Y8A mutation and PYDD5,11A (FANLYpYWAQD) has both D5A
and D11A substitutions. All the peptides carried a biotin group at
the N-terminal extremity.
2.2. Pulldown experiments
Phosphorylated and non-phosphorylated peptides were cou-
pled via the N-terminal biotin group to streptavidin sepharose
(GE Healthcare) for 1 h in 10 mM sodium phosphate buffer
pH 6.0. The beads were then mixed with lysates of MEMO-express-
ing SKBr3 cells, in the same buffer for 2 h at room temperature.
Proteins bound to the beads were subjected to SDS–PAGE and
Western blotting with MEMO antibodies, as previously reported
[9]. To observe the effect of ionic strength on MEMO/PYD1–16
interaction, complex formation was performed in the presence of
150 mM, 300 mM or 500 mM NaCl.
2.3. NMR measurements
Proton assignment was obtained using COSY, TOCSY and NOESY
experiments recorded at 300 K on a Bruker Avance 600 spectrom-
eter using a 2 mM peptide sample in 10 mM sodium phosphate
buffer pH 4.5 including 10% D2O. For structure calculation homo-
nuclear 2D-NOESY spectra were recorded using various mixing
times (80, 150 and 250 ms). The program TOPSPIN 2.1 was used
for data collection and processing. CARA software was used for
spectral analysis [15]. Proton assignment of PYD1–16 was depos-
ited at the BMRB (BMRB16495).
2.4. Structure calculation
On the basis of sequential and medium range nOes, the struc-
ture calculation of PYD1–16 was performed with the program
CYANA 2.1 using a tyrosine residue instead of the phosphotyrosine
[16]. A family of 15 structures was retained. The phosphorylationC-ter N-ter
A
C
Fig. 2. Structure of pTyrD-containing ErbB2 peptide. (A) Ensemble of the backbone trace
energy conformer of PYD1–16. Phosphotyrosine side chain of pTyr9 is shown in stick re
MEMO. PYD1–16 peptide is shown in backbone trace. (D) Electrostatic potential surfac
shown in red and basic residues in blue.of pTyr9 (pTyrD) was generated using the lowest energy conforma-
tion and CHARMMforce-ﬁeld [17] on the CHARMM-GUI web-based
graphical interface (http://www.charmm-gui.org). Electrostatic
potential was obtained using PBEQ solver [18]. Structures were
represented using PyMOL program (http://www.pymol.org).
2.5. Docking experiments
HADDOCK (High Ambiguity Driven protein–protein DOCKing)
version 2.0, uses biochemical or biophysical data as ambiguous
interaction restraints [14]. The software has been implemented
in CNS for structure calculations. The docking protocol requires
MEMO (PDB ID 3BCZ) and PYD1–16 (PDB ﬁle of the lowest energy
conformation) PDB ﬁles and ambiguous interaction restraints. The
experimental restraints were obtained from the previous mutants
for MEMO (Trp16, His49, His81, His192 and Cys244) and pTyr9 for
the phosphopeptide. The docking consists of three stages: random-
ization of orientations and rigid body energy minimization,
semi-rigid simulated annealing in torsion angle space and ﬁnal
reﬁnement in Cartesian space with explicit solvent. During simu-
lated annealing and water reﬁnement, the amino acids are allowed
to move to optimize the interface packing. The ﬁnal structures are
clustered using pairwise backbone RMSD at the interface and ana-
lyzed according to their average interaction energies and their
average buried surface area.
3. Results
3.1. Identiﬁcation of the interacting sequence
We have generated a series of PYD1–16 derived peptides and
used pulldown experiments to investigate the binding of these
peptides to MEMO. Replacement of pTyr9 by either unphosphory-
lated tyrosine or glutamate induced a drastic reduction of the
complex formation, conﬁrming that the phosphotyrosine is essen-
tial for MEMO/PYD1–16 interaction (Fig. 1A and B). Then, we have
generated three truncated peptides (PYD1–10, PYD4–13 and
PYD7–16). Pull down experiments with PYD1–10 showed that
deletion of the last six residues at the C-terminus led to a drastic




s of the 15 lowest energy conformers of PYD1–16. (B) Backbone trace of the lowest
presentation and annotated PTR-9. (C) Electrostatic potential surface interaction of
e of PYD1–16. Acidic residues (Asp5, Asp11, Asp13, Glu16 and pTyr9 (PTR-9)) are
Table 1
Intermolecular hydrogen bonds found in MEMO/PYD complex.
MEMO PYD Distance (Å)
Hydrogen bonds His192 HE2 pTyr9 O1P 1.81
Cys244 HG pTyr9 O1P 2.12
His49 HE2 pTyr9 O3P 1.61
His81 HD1 pTyr9 O3P 1.57
Trp16 HE1 Phe4 O 2.35
Tyr54 OH Asp5 OD2 1.68
Arg196 HH11 Asn6 OD1 2.44
His 82 HE2 Tyr8 OH 1.82
Arg198 HH12 Asp11 OD2 1.73
Arg198 HH21 Asp13 O 1.89
His81 HE2 Asp13 OD1 1.59
H192 HD1 Asp13 OD2 1.64
His240 HE2 Glu16 OE1 1.68
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residues was also drastically dropped (Fig. 1A and B) demonstrat-
ing that the residues located at the N-terminus of the peptide were
essential for peptide recognition by MEMO. However, pull down
experiments with the PYD4–13 peptide revealed an afﬁnity for
MEMO similar to the PYD1–16 phosphopeptide indicating that this
core sequence is required for MEMO/PYD interaction.
3.2. Structure determination of the pTyrD-encompassing ErbB2
peptide
The structure of PYD1–16 peptide was investigated by NMR.
Assignment of 15 spin systems was obtained from COSY, TOCSY
and NOESY spectra. On the basis of 62 sequential and 19 medium
range nOes (Figs. S1 and S2), the structure of PYD1–16 was calcu-
lated with CYANA. A family of 15 structures has been retained with
an average pairwise rms deviation of 1.77 Å (Table S1 and Fig. 2).
The average structure indicated that the peptide contained a
helical structure from residues Phe4 to Trp10 (numbering corre-
sponds to the positions in the PYD1–16 peptide). Phosphorylation
of pTyr9 was obtained using CHARMM-GUI web interface [19].
3.3. Structural model of MEMO/PYD1–16 complex
On the basis of MEMO X-ray structure (3BCZ) and PYD1–16
NMR structure, we have performed docking experiments using
HADDOCK [14]. In the 200 models, the phosphotyrosine is located
in the large cleft of MEMO, indicating that this interaction is essen-
tial for the complex formation. We retained the most favorable
solution in terms of intermolecular interaction energy (Fig. 3).Fig. 3. Best structural model of MEMO/PYD1–16 complex resulting from HADDOCK. (A) S
the complex corresponding to a rotation of 90 compare to (A). (C) Closer view of the inte
yellow. (D) Closer view of the interacting site indicating side chain intermolecular interIn this model, the elongated phosphopeptide is located in a
large groove of MEMO structure, resulting in an interacting surface
of 926.4 Å2 (Fig. 3A and B). The charged surface of the peptide
including pTyr9 is anchored to MEMO interface through hydrogen
bonds (Fig. 3C and D). The interface analysis was done using PISA
server [20] and VMD. Intermolecular hydrogen bonds resulting
from the complex formation are summarized in Table 1. Fig. 3C
highlights the hydrogen bonds involved in the phosphate group
stabilization. The three histidine residues (His49, His81 and
His192) of the vestigial dioxygenase active site, and also Cys244
form hydrogen bonds with oxygen atoms of the phosphate group.
The three histidine residues have the same orientation as they haveurface representation of the complex; PYD1–16 is shown in yellow. (B) Side view of
racting site showing hydrogen bonds associated to the phosphate group of pTyr9, in
actions. PYD1–16 is in yellow.
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position as the metal in LigB and Ygid. MEMO Trp16 known to play
a major role in PYD1–16/MEMO interaction [9] was found in the
environment of the phosphate group and no far of MEMO Phe4;
however, PYDF4A substitution did not affect the complex formation
indicating that MEMO Trp16/PYD Phe4 interaction is not essential
for the binding. Fig. 3D shows that residues Ser1 to Ala3 and Pro14
to Glu16 of PYD1–16 are weakly involved in protein–protein inter-
actions; these data are in very good agreement with our results on
pull down experiments performed on the short derived peptides
that indicated PYD4–13 as a minimum required sequence.
Concerning the hydrogen bonds found at the complex interface
(Table 1), even if we observed poor effects of salts on the complex
formation, double and triple mutations of Asp5, Asp11 and Asp13
revealed signiﬁcant effects on the complex formation, underlining
the implication of these residues at the interaction site (Fig. 1).
These data are in agreement with the minimal length found for
ErbB2 peptide from Phe4 to Asp13, including Asp5, Asp11 and
Asp13. PYD Asp5 is involved in a hydrogen bond with MEMO
Tyr54. Previous replacement of this residue was found not essen-
tial but diminished pYD binding [9]. PYD Asp13 is found in a strong
interaction with His81 and His192, two ligands of the pTyr phos-
phate group, being essential for the complex formation. Concern-
ing PYD Glu16, the high afﬁnity of PYD4–13 for MEMO suggests
a weak importance of this residue in the complex formation. Final-
ly, the length of the hydrogen bond observed between MEMO
Arg196 and PYD Asn6, and the observation that MEMO Arg196
mutation did not affect the complex [9], suggest that this bond is
not essential for MEMO/ErbB2 interaction. It is to be noticed that
PYDY8A substitution induces an important effect on the complex
formation indicating that this residue is very important for the
interaction.
4. Discussion
Phosphorylation on tyrosine residues creates binding sites for
modular phosphoprotein-binding domains to form multiprotein
complexes, and to provide a reversible way to regulate protein–
protein interactions both spatially and temporally [6]. ErbB2 recep-
tor is a multidomain protein containing an extracellular domain, a
transmembrane helix and an intracellular region constituted of a
kinase domain and an additional unstructured C-terminal tail
[21]. Although the structures of the extracellular and kinase do-
mains have been determined, no structural information on the
extended peptide has been reported. Analysis of the sequence
surrounding the ﬁve main autophosphorylation sites in ErbB2
C-terminal extremity [22] shows that pTyrB is part of a SH2 con-
sensus sequence (pYVNQ), while pTyrC and pTyrE are included in
a PTB consensus sequence (XNPXpY). In contrast, pTyrD is included
in a distinct sequence motif (FDNLYpYWDQD), which results in a
well structured peptide that allow interaction with MEMO, a new
type of phosphotyrosine binding protein [9].
The pH-dependence of MEMO/PYD1–16 binding suggested that
histidine residues were particularly important for the interaction
and may balance the charge of the phosphorylated tyrosine. A large
cleft is present in MEMO structure and amino acid substitutions of
histidine residues in this cleft, strongly diminished PYD1–16
binding [9]. Our study describing the structure and minimal
sequence requirement for PYD1–16 ErbB2 peptide binding to
MEMO provides valuable insights for the understanding of
MEMO–PYD1–16 interaction. The present data clearly demonstrate
that a phosphotyrosine residue is essential for MEMO/PYD1–16interaction, and that additional interactions involving PYD Asp5,
Tyr8, Asp11 and Asp13 are very important for the complex
formation.
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